Philips has substantially resolved the Respironics CPAP recall litigation with a US class settlement, removing the major equity overhang. The Diagnosis & Treatment (Image Guided Therapy, Ultrasound) division remains the highest-quality earnings engine, and Personal Health is structurally improving. China stimulus on hospital equipment procurement provides cyclical recovery. Margin expansion targets remain credible but require sustained execution. Premium imaging share gains versus GE HealthCare and Siemens Healthineers are uneven.
Thesis reviewed May 29, 2026
Koninklijke Philips NV is headquartered in Netherlands, which is currently showing moderate signals.
🇳🇱Netherlands53NEUTRALView Netherlands risk detail →🏥Healthcare33NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| CVS | CVS Health Corporation | 40 | +15% | ↓3% | AVOID |
| HCA | HCA Healthcare Inc. | 40 | +9% | ↓3% | EARLY |
| UNH | UnitedHealth Group Inc. | 37 | +16% | ↓3% | AVOID |
| TMO | Thermo Fisher Scientific Inc. | 37 | +11% | ↓3% | EARLY |
| CI | The Cigna Group | 37 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 37 | +7% | ↓3% | NEUTRAL |
| TEVA | Teva Pharmaceutical Industries Ltd. | 37 | +9% | ↓3% | NEUTRAL |
Investors who hold PHG may also have indirect exposure through these country funds.
Philips finalizes USD1.1bn Respironics consumer class action settlement
China VBP medical equipment procurement resumes orders for imaging
Estimates · Yahoo Finance · Not audited figures